Best Life Sciences Tech Companies in South Korea
The 57 best Life Sciences Tech companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Standigm.
Ranking the best Life Sciences Tech companies in South Korea by disclosed equity funding, this directory tracks 57 firms sitting on a combined $215M in total capital raised. No unicorns yet, but the momentum is real. Standigm leads the pack at $70M, with Galaxy close behind at $47M, and a cluster of earlier-stage bets like Portrai, AIGEN Sciences and Surginex stacking up in the $9-10M range. Backers including DSC Investment, Mirae Science and Technology Holdings and InterVest are clearly circling this market with intent. And according to LifeSciencesIntelligence, the sector's digital infrastructure is scaling fast, with regulatory compliance and intellectual property protection driving much of that enterprise demand.
So what's the underlying pulse? Median install growth across health and life sciences apps is running at roughly +43% year-over-year, which tells you end-user adoption isn't lagging the investment side. I'd watch that gap between Standigm's funding position and the next tier closely, because 2024 research points to next-generation platforms reshaping competitive positioning across life sciences tech faster than most market maps account for. South Korea's cohort is still pre-unicorn, but the funding architecture here looks like a sector building toward its first breakout company.
- EVERSANA
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Standigm AI-based platform for drug discovery and development 48Patents top 19%Moat top 19%Innovation top 21%Talent top 28% All 10 signals ▾Patentstop 19% Moattop 19% Innovationtop 21% Talenttop 28% AItop 30% Fundingtop 36% Globalbottom 42% Newsbottom 27% Techbottom 21% Marketbottom 18% Patents: 101 patents matched (strict assignee match) · 77 filings since 2022 vs 24 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 101 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $70M | 60 mo ago | Series C | Jinhan Kim Co-Founder & CEO | 2015 | — | 101 patents Patents concentrated in health & consumer products | — |
| 2 | Galaxy Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various… 37Funding top 28%News top 36%Talent bottom 49%Market bottom 44% All 5 signals ▾Fundingtop 28% Newstop 36% Talentbottom 49% Marketbottom 44% Globalbottom 33% Funding: Raised $47.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding rank vs industry peers · Fliar Intelligence Index 37/100 | $47M | 5 mo ago | Series B | Chaok Seok CEO | 2020 | — | — | — |
| 3 | Pharmcadd Provider of CAAD based drug discovery platform | $22M | 63 mo ago | Series B | Woo Wook Founder | 2019 | — | 21 patents AI-based protein structure prediction and piperidine-derived drug discovery | — |
| 4 | Deargen Developer of AI-based drug discovery platform for rare and intractable diseases | $17M | 52 mo ago | Series B | Gilsu Kang CEO | 2016 | — | 72 patents AI-driven small‑molecule design and target interaction prediction for drug discovery | — |
| 5 | Oncocross Provider of AI-based drug discovery platform | $14M | 70 mo ago | Public | Jin Choi Co-Founder | 2015 | PHPCodeIgniterBootstrap+14 | 132 patents AI-driven drug discovery and predictive therapeutics for cancer, kidney, and muscle diseases | 1 partnership |
| 6 | JNPMEDI Provider of cloud-based clinical trail data management solutions | $10M | 43 mo ago | Series A | Kwunho Jeong Chief Executive Officer | 2020 | ImwebSentryZendesk+24 | 24 patents AI-powered automation of clinical trial documentation, data linking, and reporting workflows | 2 partnerships · 1 expansion · 2 awards |
| 7 | Portrai Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification 22Patents top 37%Funding top 38%Innovation top 41%Global bottom 35% All 5 signals ▾Patentstop 37% Fundingtop 38% Innovationtop 41% Globalbottom 35% Marketbottom 22% Patents: 29 patents matched (strict assignee match) · 29 filings since 2022 vs 0 in 2017-21 Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $10M | 7 mo ago | Series B | — | 2021 | — | 29 patents Patents concentrated in computing, sensing & instrumentation | — |
| 8 | SURGINEX Provider of AI-based drug discovery platform 24AI top 35%Moat top 38%Patents top 39%Innovation top 48% All 9 signals ▾AItop 35% Moattop 38% Patentstop 39% Innovationtop 48% Fundingtop 48% Techbottom 47% Talentbottom 45% Globalbottom 36% Marketbottom 13% AI: Product described with: ai-based, artificial intelligence Moat: Editorial + unicorn rating 4/10 · IP moat: 19 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $9M | 27 mo ago | Series A | Sejun Kim CEO | 2020 | Wix eCommerceWixSentry+12 | 19 patents Nanoparticle lipid carriers and hydrogel systems for biliary drug delivery and AI epitope design | — |
| 9 | AIGEN Sciences AI-based drug discovery and designing tool for researchers 35AI top 30%Moat top 38%Funding top 42%Patents top 46% All 8 signals ▾AItop 30% Moattop 38% Fundingtop 42% Patentstop 46% Innovationtop 48% Talentbottom 49% Globalbottom 31% Marketbottom 25% AI: Classified as an AI company · Product described with: ai-based Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $9M | 12 mo ago | Series A | Jaewoo Kang CEO | 2021 | — | 7 patents Patents concentrated in chemistry & materials | — |
| 10 | Bionsight Provider of AI-based data analysis software for drug development | $4M | 34 mo ago | Series A | — | 2019 | — | 7 patents Patents concentrated in computing, sensing & instrumentation | — |
| 11 | ACTNOVA AI vision-based behavior test platform provider | $2M | 29 mo ago | Seed | Daesoo Kim Founder | 2020 | — | 5 patents Real-time animal behavior monitoring and video analytics using computer vision and streaming technologies | — |
| 12 | ReDWit Provider of AI and blockchain based research management platform | $660K | 72 mo ago | Seed | Jiwon Kim CEO | 2019 | — | 12 patents Decentralized IPFS content ID distribution and blockchain-based data management/encryption. | — |
Top 12 Life Sciences Tech companies in South Korea
#1
Series B · Seoul, Seoul · founded 2020 · 23 employees$47Mraised▾
Provider of a drug discovery platform that integrates AI, physics, and chemistry to design various biomolecules. The technology enables the prediction of solubility, binding affinity, and other properties of these molecules, which is crucial in the drug discovery process. The platform helps in molecular design, protien structure prediction, protien interaction and prediction for drug development.
- Feb 2026Series B$29M
- 2022Series A$18M
#2
Series B · Seoul, Seoul · founded 2021 · 7 employees$9.9Mraised▾
Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification. The platform allow researchers to analyse the pathophysiology of diseases and discovers biomarkers, identify targets for new drugs, analyse the mode of action of drugs, and discover biomarkers.
- Dec 2025Series B$9.9M
#3
Series A · Seoul, Seoul · founded 2021 · 8 employees$8.8Mraised▾
AI-based drug discovery and designing tool for researchers. The company has developed a proprietary tool AIGEN Discovery that assists with the discovery and designing of new drugs. The system can be used for drug targeting, data analysis, novel compounds optimization, and more.
- Jul 2025Series A—
- Oct 2024Series A$8.8M
#4
Series A · Seoul, Seoul · founded 2020 · 6 employees$9.3Mraised▾
Operator of a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company develops drugs with capabilities ranging from artificial intelligence-based new drug platforms to molecular biology experiments, animal experiments, and clinical trials, helping patients to recover soon from the new drugs.
#5
Series C · Seoul, Seoul · founded 2015 · 3 employees$69.7Mraised▾
AI-based platform for drug discovery and development. The company has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Its products include DarkMolFactory for molecular design, Standigm ASK for target discovery, Standigm BEST for lead design, and Standigm Insight for drug repurposing.
- Jul 2021Series C$10M
- Mar 2021Series C$44.5M
- Mar 2019Series B$11.5M
- Aug 2016Series A$3.4M
#6
Seed · Daejeon, Daejeon · founded 2020 · 7 employees$2.5Mraised▾
AI vision-based behavior test platform provider. It offers a web application to analyze videos. It leverages AI and machine learning to identify and visualize behaviors. Users can import video files by drag and drop and experiment with conventional behavioral apparatuses or customize.
- Feb 2024Seed$2.5M
#7
Series A · Incheon, Incheon · founded 2020 · 48 employees$10.3Mraised▾
Provider of cloud-based clinical trail data management solutions. It is a SaaS-based platform offering digitalization services to various fields of pharmaceuticals, bio, digital medicines, and digital medical devices.
- Nov 2022Series A$10.3M
#8
Series B · Seoul, Seoul · founded 2016 · 39 employees$17Mraised▾
Developer of AI-based drug discovery platform for rare and intractable diseases. The company's platform comprises genome data analysis, biomarker prediction, molecule selection, and optimization. It is used for discovering new disease targets for developing small molecule precision medicine.
- Feb 2022Series B$17M
#9
Series A · Seoul, Seoul · founded 2019 · 11 employees$4.2Mraised▾
Provider of AI-based data analysis software for drug development. The companies products Glance and Skeleton have been built in order to assist researchers with the process of novel drug discovery. The software Glance uses AI technology to analyze biomedical data of protein targets and patients' biomedical literature for drug target identification. Skeleton has tools for drug designing and screening.
- Aug 2023Series A$4.2M
- Feb 2021Seed—
#10
Series B · Busan, Busan · founded 2019 · 35 employees$22Mraised▾
Provider of CAAD based drug discovery platform. The Pharmulator platform uses AI, network theory, quantum calculation, and molecular dynamics that predict protein structure to design and synthesize new drug candidates. The company is developing drugs for NAOC, cancer, Alzheimers, and covid-19.
- Mar 2021Series B$15.5M
#11
Public · Seoul, Seoul · founded 2015 · 10 employees$13.9Mraised▾
Oncross is an AI-based drug discovery platform. The platform helps in matching and reporting of drugs, the user put data of the and then through AI the software gives matching and reporting of the drug interaction.
- Sep 2020Series B$13.9M
#12
Seed · Yuseong District, Hoseo · founded 2019 · 15 employees$659.6Kraised▾
ReDWit provides an AI and blockchain-based research management platform. It uses blockchain system to digitize and authenticate research notes and uses AI to implement an auto-labeling system.
- Jun 2020Seed$659.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in South Korea
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 885 South Korea-affiliated papers.
- Ministry of Agriculture118
- Ministry of Education70
- Seoul National University53
- Yonsei University44
- Korea University36
- Gene2→26
- Genome1→10
- Transcription factor1→9
- Genome editing1→6
- Transformation (genetics)1→6
- Antimicrobial1→23
- Apoptosis1→12
- Cell culture2→10
- Cytotoxicity2→8
- Gene knockdown1→7
- Human health2→11
- Health benefits1→6
- Antibiotic resistance1→4
- Toxicity2→4
Where biotechnology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in South Korea
South Korea biotechnology patent filing is accelerating — 58,964 filings from 8,000 assignees (2016–2025), led by CJ Cheiljedang, UNIV Korea RES & BUS Found, Samsung; annual filings 4052→6791.
- CJ Cheiljedang6610
- UNIV Korea RES & BUS Found1920
- Samsung1764
- Korea Advanced INST SCI & TECH1761
- Seoul NAT UNIV R&DB Foundation1752
- Korea RES INST Of Bioscience1538
- Hanmi Pharm IND1198
- Korea RES INST Bioscience & Biot1009
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.